Navigation Links
Oxford Performance Materials and Biomet Microfixation Join Forces
Date:4/8/2013

South Windsor, CT (PRWEB) April 08, 2013

Oxford Performance Materials (OPM) and Biomet Microfixation (Biomet) have entered into an exclusive distribution agreement for OPM’s OsteoFab™ Patient Specific Cranial Device (OPSCD). Under the terms of the agreement, Biomet will have exclusive global distribution rights to the OPSCD and OsteoFab™ implants for craniomaxillofacial (CMF).

“Following the universally positive response from our initial clients, it is with great satisfaction that we announce this global strategic cooperation with Biomet,” said Scott DeFelice, President and CEO of OPM. “We concluded that Biomet was the best partner based upon their existing product mix, global market presence, exceptional focus on Patient-Specific solutions, and clear reputation as a technological leader within the cranial and orthopedic industries.” OPM and Biomet performed the first clinical application in the United States earlier this year.

OPM’s OsteoFab™ technology combines OXPEKK®-IG polymer (PEKK or polyetherketoneketone), a biocompatible material with properties like bone, with a unique additive manufacturing process to “3D print” products ranging from bespoke devices to patient-specific designs created directly from a CT or MRI scan. OXPEKK®-IG polymer has been used in implant devices for seven years and is supported by extensive biocompatibility and clinical data. OPM has recently completed a multimillion dollar capital project resulting in a state-of-the-art biomedical additive manufacturing facility located in South Windsor, CT.

“We have steadfastly held to our vision that if we could additively produce an implant designed directly from a patient’s MRI or CT in a biocompatible structural polymer, we would advance human health and well-being while respecting healthcare market realities,” said DeFelice. OPM began producing CMF implants as a contract manufacturer in late 2011 and received FDA clearance for their own OPSCD in February 2013.

About Biomet
Biomet, Inc. (http://www.biomet.com) and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses large joint reconstructive products, including orthopedic joint replacement devices, and bone cements and accessories; sports medicine, extremities and trauma products, including internal and external orthopedic fixation devices; spine and bone healing products, including spine hardware, spinal stimulation devices, and orthobiologics, as well as electrical bone growth stimulators; dental reconstructive products; and other products, including microfixation products and autologous therapies. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.

About OPM
OPM operates at the intersection of high performance polymers, additive manufacturing technologies, and the creation of structures for the biomedical and aerospace sectors. The firm currently has four operating divisions: Biomedical Devices and Parts, Biomedical Raw Materials, Industrial Parts, and Metrology Sciences. OPM was selected to participate in the National Additive Manufacturing Innovation Institute (NAMII) in 2012. OPM has obtained ISO 13485:2003 and ISO 9001:2008/AS9100C certificates and received FDA clearance in February 2013 for the OsteoFab™ Patient Specific Cranial Device.

For more information, please visit http://www.oxfordpm.com

Read the full story at http://www.prweb.com/releases/2013OPM-BIOMET/03OPM-BIOMET/prweb10585289.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
2. Oxford Finance Completes $271.4 Million Securitization Transaction
3. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
4. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
5. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
6. Achieving Optimal Performance from Single-Use Platforms, New Life Science Webinar Hosted by Xtalks
7. Stoneville Cotton Seed from Bayer CropScience Celebrates 90 Years of Performance
8. Bayer CropScience and MS Technologies’ Balance GT Soybean to Usher in Next Era of Performance and Weed Control
9. Elsevier and Kanazawa University in Japan Collaborate to Map Universitys Research Performance
10. New nanotech fiber: Robust handling, shocking performance
11. Thomson Reuters Online Resource Offers Key Trends in Scientific Research and Performance Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... Calif. (PRWEB) , ... February 24, 2017 , ... Chef ... and wine scene. Making stops in several cities, she gained a number of ... adventure began in Stellenbosch, a town in South Africa’s Western Cape province. It ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/23/2017)... NEW YORK , Feb. 23, ... , a leading digital health company, and ... of telemedicine and remote patient monitoring, announce they ... reimbursements.  DN Telehealth maximizes collaboration ... real-time, extending consultations beyond a physical clinical setting ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
Breaking Biology News(10 mins):